Triple combination of oral vinorelbine, capecitabine and trastuzumab as first-line treatment in HER2-positive metastatic breast cancer (MBC): latest results of an international phase II trial

被引：0
|
作者：
Chan, A. [1 ]
Ganju, V. [2 ]
Becquart, D. [3 ]
Conte, P. F. [4 ]
Petruzelka, L. [5 ]
Perrot, O. [6 ]
Villanova, G. [6 ]
Tubiana-Mathieu, N. [7 ]
机构：
[1] Mt Hosp, Perth, WA, Australia
[2] Frankston Hosp, Frankston, Australia
[3] AZ Middlelheim, Antwerp, Belgium
[4] Policlin Modena, Modena, Italy
[5] Gen Teaching Hosp, Prague, Czech Republic
[6] Inst Rech Pierre Fabre, Boulogne, France
[7] CHU Dupuytren, Limoges, France
来源：
EJC SUPPLEMENTS | 2007年 / 5卷 / 04期
关键词：
D O I：
10.1016/S1359-6349(07)70886-8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2124
引用
收藏
页码：221 / 222
页数：2
相关论文
共 50 条
  • [41] Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial
    Fernando Rivera
    C. Romero
    P. Jimenez-Fonseca
    M. Izquierdo-Manuel
    A. Salud
    E. Martínez
    M. Jorge
    V. Arrazubi
    J. C. Méndez
    P. García-Alfonso
    M. Reboredo
    J. Barriuso
    N. Muñoz-Unceta
    R. Jimeno
    C. López
    Cancer Chemotherapy and Pharmacology, 2019, 83 : 1175 - 1181
  • [42] Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial
    Rivera, Fernando
    Romero, C.
    Jimenez-Fonseca, P.
    Izquierdo-Manuel, M.
    Salud, A.
    Martinez, E.
    Jorge, M.
    Arrazubi, V.
    Mendez, J. C.
    Garcia-Alfonso, P.
    Reboredo, M.
    Barriuso, J.
    Munoz-Unceta, N.
    Jimeno, R.
    Lopez, C.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 83 (06) : 1175 - 1181
  • [43] Trastuzumab (Herceptin®) plus docetaxel versus docetaxel alone as first-line treatment of HER2-positive metastatic breast cancer (MBC):: results of a randomised multicentre trial
    Extra, J. M.
    Cognetti, F.
    Maraninch, D.
    Snyder, R.
    Mauriac, L.
    Tubiana-Hulin, M.
    Chan, S.
    Grimes, D.
    Anton, A.
    Marty, M.
    EJC SUPPLEMENTS, 2004, 2 (03): : 125 - 126
  • [44] All oral combination of vinorelbine and capecitabine as a first line treatment in patients (pts) with metastatic breast cancer (MBC)
    Shehata, S.
    Khalaf, M.
    ANNALS OF ONCOLOGY, 2017, 28
  • [45] A Phase II Trial of Oxaliplatin and Trastuzumab in the Treatment of HER2-Positive Metastatic Breast Cancer
    Yardley, Denise A.
    Daniel, Davey
    Stipanov, Michael
    Drosick, D. Randolph
    Mainwaring, Mark
    Peyton, James
    Shastry, Mythili
    Hainsworth, John D.
    CANCER INVESTIGATION, 2010, 28 (08) : 865 - 871
  • [46] Phase II Interventional Study (N0337) of Capecitabine in Combination With Vinorelbine and Trastuzumab for First- or Second-Line Treatment of HER2-Positive Metastatic Breast Cancer: A North Central Cancer Treatment Group Trial
    Tan, Winston W.
    Allred, Jacob B.
    Salim, Muhammad
    Flynn, Patrick
    Fishkin, Paul A. S.
    Stella, Philip J.
    Wiesenfeld, Martin
    Bernath, Albert M.
    Fitch, Tom R.
    Perez, Edith A.
    CLINICAL BREAST CANCER, 2012, 12 (02) : 81 - 86
  • [47] Phase II trial of weekly vinorelbine and trastuzumab as first-line therapy in patients with HER2+ metastatic breast cancer
    Jahanzeb, M
    Mortimer, JE
    Yunus, F
    Irwin, DH
    Speyer, J
    Koletsky, AJ
    Klein, P
    Sabir, T
    Kronish, L
    ONCOLOGIST, 2002, 7 (05): : 410 - 417
  • [48] Trastuzumab as first-line therapy in HER2-positive metastatic breast cancer patients
    Del Mastro, Lucia
    Lambertini, Matteo
    Bighin, Claudia
    Levaggi, Alessia
    D'Alonzo, Alessia
    Giraudi, Sara
    Pronzato, Paolo
    EXPERT REVIEW OF ANTICANCER THERAPY, 2012, 12 (11) : 1391 - 1405
  • [49] Phase II trial of capecitabine and vinorelbine as first-line chemotherapy for metastatic breast cancer patients
    Ghosn, M
    Kattan, J
    Farhat, F
    Younes, F
    Gasmi, J
    ANTICANCER RESEARCH, 2006, 26 (3B) : 2451 - 2456
  • [50] Phase I/II trial of ruxolitinib in combination with trastuzumab in metastatic HER2-positive breast cancer
    Kalinsky, Kevin
    Chi, Dow-Chung
    Lee, Shing Mirn
    Adelson, Kerin B.
    Crew, Katherine D.
    Chuang, Ellen
    Makower, Della
    Hershman, Dawn L.
    Califano, Andrea
    Silva, Jose
    Maurer, Matthew A.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345